Results 121 to 130 of about 42,096 (271)

Algorithms in Allergy: Hereditary Angioedema

Allergy, EarlyView.
Konrad Bork, Markus Magerl, Emel Aygören‐Pürsün, Henriette Farkas   +3 more
wiley   +1 more source

Garadacimab for the long‐term prophylaxis of hereditary angioedema

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Hereditary angioedema (HAE), a rare and debilitating disease characterized by recurrent and spontaneous attacks of tissue swelling, has a high unmet therapeutic need, with many patients experiencing insufficient disease control with current prophylactic treatments.
Emel Aygören‐Pürsün, Regina Treudler, Petra Staubach, Inmaculada Martinez Saguer, Thomas Linhoff, Markus Magerl   +5 more
wiley   +1 more source

Case Reports : Isolated intestinal angioedema induced by an ACE-inhibitor [PDF]

, 2015
INTRODUCTION: We report a case of isolated angioedema in a patient who presented with severe abdominal pain shortly after starting Lisinopril for treatment of hypertension. CASE DESCRIPTION: A 26 year old female presented with diffuse abdominal pain with
Chela, Harleen, Hampel, Paul, Irish, John, Parker, Rochelle   +3 more
core  

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. [PDF]

, 2016
AimsIn this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril ...
Claggett, Brian, Desai, Akshay S, Lefkowitz, Martin, McMurray, John JV, Packer, Milton, Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators, Rouleau, Jean, Shi, Victor, Solomon, Scott D, Swedberg, Karl, Teerlink, John R, Vardeny, Orly, Zile, Michael R   +12 more
core   +1 more source

Kinetic and structural characterisation of domain‐specific angiotensin I‐converting enzyme inhibition by captopril, rentiapril and zofenoprilat

The FEBS Journal, EarlyView.
Angiotensin I‐converting enzyme (ACE) contains two catalytic domains (nACE and cACE) and is a key therapeutic target for hypertension and cardiovascular disease. Current ACE inhibitors (ACEi) nonselectively inhibit both domains, causing adverse effects. Selective inhibition requires an understanding of domain‐specific binding.
Kyle S. Gregory, Vinasha Ramasamy, Edward D. Sturrock, K. Ravi Acharya   +3 more
wiley   +1 more source

Gene Editing for Haemophilia—The Next Frontier

Haemophilia, EarlyView.
ABSTRACT The recently approved haemophilia A and B gene therapies via adeno‐associated virus (AAV) showed a promising therapeutic response after a single injection, but there are still limitations, including the potential loss of transgene expression and restriction in adults.
Mirko Pinotti, Gregory A. Newby, Sundar Selvaraj, Steven W. Pipe   +3 more
wiley   +1 more source

Perceived Acquired Resistance to Omalizumab in Obese Patients With Chronic Spontaneous Urticaria

Clinical &Experimental Allergy, EarlyView.
Francisco Martins, Ilaria Trave, Sofia Pereira, Margarida Gonçalo   +3 more
wiley   +1 more source

Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO‐CGRP study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study aimed to evaluate demographic characteristics, treatment effectiveness, and safety outcomes in patients with migraine undergoing anti‐calcitonin gene‐related peptide (CGRP) treatments regarding the presence of autoimmune diseases. Background CGRP has an important role in migraine pathophysiology through neuronal modulation
María Clara García‐Castillo, Álvaro Sierra‐Mencía, Edoardo Caronna, Daniel Toledo‐Alfocea, Alex Jaimes, Sarai Urtiaga, Javier Casas‐Limón, Albert Muñoz‐Vendrell, Sonia Santos‐Lasaosa, Valvanuz García Martín, Guillermo Martín Ávila, Marcos Polanco, Maria Dolores Villar‐Martínez, Cristina Trevino‐Peinado, Laura Rubio‐Flores, Antonio Sánchez‐Soblechero, Leonardo Portocarrero Sánchez, Elisa Luque‐Buzo, Alberto Lozano‐Ros, Ana Beatriz Gago‐Veiga, Javier Díaz‐De‐Terán, Andrea Recio García, Javiera Canales Rodríguez, Andrea Gómez García, Marta González Salaices, Sergio Campoy, Ane Mínguez‐Olaondo, Stefania Maniataki, Vicente González‐Quintanilla, Jesús Porta‐Etessam, María‐Luz Cuadrado, Ángel Luis Guerrero Peral, Patricia Pozo‐Rosich, Jaime Rodríguez‐Vico, Mariano Huerta‐Villanueva, Julio Pascual, Peter J. Goadsby, Alicia Gonzalez‐Martinez   +37 more
wiley   +1 more source

Hereditary angioedema.Treatment of acute attacks in Argentina [PDF]

, 2014
En el mundo, el angioedema hereditario (HAE) afecta a 1 de cada 50 000 personas. Produceepisodios de angioedema cutáneo, abdominal y laríngeos que generan gran incapacidad. Lamortalidad por la enfermedad oscila entre 15 y 50%.
Fernández Romero, Diego S., Malbran, Eloisa, Malbrán, Alejandro, Menéndez, Alejandra   +3 more
core  

Completion of the Icatibant Outcome Survey and What We Learned

Clinical &Experimental Allergy, EarlyView.
Laurence Bouillet, Werner Aberer, Teresa Caballero, Anete S. Grumach, Hilary J. Longhurst, Alissa Dangel, Natalie Khutoryansky, Irmgard Andresen, Andrea Zanichelli   +8 more
wiley   +1 more source